Clinical validation of a mobility monitor to measure and predict health outcomes
| ISRCTN | ISRCTN12051706 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN12051706 |
| IRAS number | 289543 |
| Secondary identifying numbers | IRAS 289543 |
- Submission date
- 09/12/2020
- Registration date
- 10/12/2020
- Last edited
- 25/06/2025
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Other
Plain English summary of protocol
Background and study aims
The ability to move is important for general well-being. Ageing and chronic health conditions can lead to a loss of mobility and a loss of independence. In order to treat mobility loss, tools are needed that can detect and accurately measure mobility. Existing measures of mobility (based on self-reporting and one-off tests) are highly limited. Wearable digital technology (a small device worn on the body) that can be used in the home and the community can provide a simple, accurate and low-cost measure of mobility. The researchers have validated a wearable mobility monitor which can accurately measure how well a person walks by measuring aspects of mobility such as speed and symmetry. The aim of this study is to investigate the ability of the mobility monitor to measure and predict outcomes in a variety of health conditions. The digital assessment of mobility developed in this study will be used in clinical trials and in clinical practice.
Who can participate?
People aged 18 or over who have been diagnosed with Parkinson’s disease, chronic obstructive pulmonary disease, multiple sclerosis and recent hip fracture.
What does the study involve?
Participants will attend a baseline visit and four follow up visits every 6 months (study length is 24 months). Each visit will last around 3 hours and will involve the completion of a range of questionnaires and assessments:
- Descriptive measures (i.e. height and weight, living arrangements, smoking and alcohol use and vision).
- Clinical assessments (i.e. level of function and disability, quality of life, frailty, fall and injury history, medical history, medication, blood pressure, pain, fatigue and muscle/fat mass).
- Psychological assessments (i.e. brief memory test, fear of falling and depression)
- Physical assessments (i.e. balance tests, 6-minute walk test and muscle strength)
- Disease-specific assessments measuring the severity of participant's health condition
At the end of each visit, participants will be asked to wear a mobility monitor around their waist for 7 days. The monitor will measure several aspects of mobility such as walking speed and step length.
What are the possible benefits and risks of participating?
There will be no direct benefit to participating in this study. Participants will be making a valuable contribution to the development of a digital assessment of mobility. There should be no major disadvantages or risks in taking part in this study. It is possible that participants will feel tired during and after the study visits, but opportunities to rest times will be given.
Where is the study run from?
Newcastle University (UK)
When is the study starting and how long is it expected to run for?
October 2018 to May 2024
Who is funding the study?
Innovative Medicines Initiative 2 Joint Undertaking (EU)
Who is the main contact?
Isabel Neatrour, Isabel.Neatrour@newcastle.ac.uk
Prof Lynn Rochester, lynn.rochester@newcastle.ac.uk
Contact information
Scientific
Mobilise-D Office
Room 3.27
The Catalyst
3 Science Square
Newcastle Helix
Newcastle upon Tyne
NE4 5TG
United Kingdom
| Phone | +44 (0)191 2081406 |
|---|---|
| isabel.neatrour@newcastle.ac.uk |
Scientific
Newcastle University
Clinical Ageing Research Unit
Campus for Ageing and Vitality
Newcastle upon Tyne
NE4 5PL
United Kingdom
| Phone | +44 (0)191 208 1291 |
|---|---|
| lynn.rochester@newcastle.ac.uk |
Study information
| Study design | Observational non-interventional study |
|---|---|
| Primary study design | Observational |
| Secondary study design | Longitudinal study |
| Study setting(s) | Other |
| Study type | Other |
| Participant information sheet | Not available in web format, please use the contact details to request a patient information sheet |
| Scientific title | Validating digital mobility assessment using wearable technology – the Mobilise-D Clinical Validation study |
| Study acronym | Mobilise-D CVS |
| Study objectives | The Mobilise-D Project aims to link digital assessments of mobility to clinical outcomes for regulatory and clinical endorsement. The Clinical Validation Study is the second stage of this project and aims to use a technically validated device-algorithm pair to link digital mobility outcomes (DMOs) to clinical endpoints in four chronic conditions. |
| Ethics approval(s) | Approved 15/01/2021, London - Bloomsbury Research Ethics Committee (HRA RES Centre Manchester, Barlow House 3rd Floor, 4 Minshull Street, Manchester, M1 3DZ, UK; +44 (0)207 104 8196; nrescommittee.london-bloomsbury@nhs.net), ref: 20/PR/0792 |
| Health condition(s) or problem(s) studied | Parkinson’s disease (PD), multiple sclerosis (MS), chronic obstructive pulmonary disease (COPD), proximal femoral fracture (PFF) |
| Intervention | Participants will attend a baseline visit and four follow up visits every 6 months (study length is 24 months). Each visit will involve the completion of questionnaires and assessments including: 1. Descriptive measures (i.e. height and weight, living arrangements, smoking and alcohol use and vision) 2. Clinical assessments (i.e. level of function and disability, quality of life, frailty, fall and injury history, medical history, medication, blood pressure, pain, fatigue and muscle/fat mass) 3. Psychological assessments (i.e. brief memory test, fear of falling and depression) 4. Physical assessments (i.e. balance tests, 6-minute walk test and muscle strength) 5. Disease-specific assessments measuring the severity of the participant's health condition At the end of each visit, participants will be asked to wear a mobility monitor around their waist for 7 days. The monitor will measure several aspects of mobility such as walking speed and step length. |
| Intervention type | Device |
| Pharmaceutical study type(s) | |
| Phase | Not Applicable |
| Drug / device / biological / vaccine name(s) | Not provided at time of registration |
| Primary outcome measure | Current primary outcome measure as of 27/10/2022: Global primary outcome: Change in the functional component score of the Late-Life Functional Disability Index (LLFDI) during 12-month follow-up. There are also disease-specific primary outcomes for each cohort: 1. PD Cohort: Fall frequency during first 12 months follow-up, collected via face-to-face interview, participant-completed falls diaries and hospital records at baseline, 6 and 12 months. 2. MS Cohort: Fall frequency during first 12 months follow-up, collected via face-to-face interview, participant-completed falls diaries and hospital records at baseline, 6 and 12 months. 3. COPD Cohort: Occurrence of moderate-to-severe COPD exacerbations during the first 12 months of follow-up, collected via face-to-face interview, participant-completed falls diaries and hospital records at baseline, 6 and 12 months. 4. PFF Cohort: Admission to a care home assessed from patient records at 6 months follow-up. _____ Previous primary outcome measure: Global primary outcome: Change in the functional component score of the Late-Life Functional Disability Index (LLFDI) during 24-month follow-up, measured at baseline, 6, 12, 18 and 24 months There are also disease-specific primary outcomes for each cohort: 1. PD Cohort: Fall frequency during 24 months follow-up, collected via face-to-face interview, participant-completed falls diaries and hospital records at baseline, 6, 12, 18 and 24 months 2. MS Cohort: Fall frequency during 24 months follow-up, collected via face-to-face interview, participant-completed falls diaries and hospital records at baseline, 6, 12, 18 and 24 months 3. COPD Cohort: Occurrence of moderate-to-severe COPD exacerbations during the first 12 months of follow-up, collected via face-to-face interview, participant-completed falls diaries and hospital records at baseline, 6 and 12 months 4. PFF Cohort: Admission to a care home assessed from patient records at 6 months follow-up |
| Secondary outcome measures | Current secondary outcome measures as of 27/10/2022: 1. Assess predictive capacity of DMOs over 12 months. 2. Assess construct validity of DMOs over 12 months. 3. Assess ability of DMOs to detect change over 12 months. 4. Estimate the Minimum Important Difference of DMOs to measure change over 12 months. 5. Describe real-world walking behaviour with DMO’s. _____ Previous secondary outcome measures: There are no secondary outcome measures |
| Overall study start date | 26/10/2018 |
| Completion date | 25/05/2024 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | Both |
| Target number of participants | 2,400 (600 per cohort) |
| Total final enrolment | 2388 |
| Key inclusion criteria | Current inclusion criteria as of 19/07/2021: All participants: 1. Adults aged 18 or over 2. Able to walk 4 meters independently with or without walking aids 3. Anticipated availability for repeated study visits over 24 months 4. Ability to consent and comply with any study specific procedures. 5. Willingness to wear the McRobert’s body sensor (DynaPort MoveMonitor) 6. Able to read and write in first language in the respective country PD Cohort: 1. Patients with the clinical diagnosis of PD according to the recent criteria of the Movement Disorder Society 2. Hoehn & Yahr stage I-III. MS Cohort: 1. A diagnosis of MS based on the revised McDonald’s criteria 2. EDSS score of 3.0 - 6.5 3. Clinical evidence of disability worsening over the previous two years COPD Cohort: 1. Diagnosis of COPD (post-bronchodilator forced expiratory volume in the first second (FEV1) to forced vital capacity (FVC) ratio <0.70 2, Clinical stability, defined as at least 4 weeks after the onset of the last exacerbation 3. Current or ex-smokers with a smoking history equivalent to at least 10 pack years (1 pack year = 20 cigarettes smoked per day for 1 year) PFF Cohort: 1. Surgical treatment (fixation or arthroplasty) for a low-energy fracture of the proximal femur (ICD-10 diagnosis S72.0, S72.1, S72.2) as diagnosed on X-rays of the hip and pelvis. Between 3 days and 52 weeks post-surgery 2. Aged 45 years or older _____ Previous inclusion criteria: All participants: 1. Adults aged 18 or over 2. Able to walk 4 meters independently with or without walking aids 3. Anticipated availability for repeated study visits over 24 months 4. Ability to consent and comply with any study specific procedures. 5. Willingness to wear the McRobert’s body sensor (DynaPort MoveMonitor) 6. Able to read and write in first language in the respective country PD Cohort: 1. Patients with the clinical diagnosis of PD according to the recent criteria of the Movement Disorder Society 2. Hoehn & Yahr stage I-III. MS Cohort: 1. A diagnosis of MS based on the revised McDonald’s criteria 2. EDSS score of 3.0-6.5. 3. Evidence of confirmed disability progression within the 12 months prior to screening (defined by a 6-month confirmed EDSS increase of 1.0-point for participants if the EDSS score was 3.0 to 5.5 and a 0.5-point if the EDSS score was 6.0 to 6.5). COPD Cohort: 1. Diagnosis of COPD (post-bronchodilator forced expiratory volume in the first second (FEV1) to forced vital capacity (FVC) ratio <0.70 2, Clinical stability, defined as at least 4 weeks after the onset of the last exacerbation 3. Current or ex-smokers with a smoking history equivalent to at least 10 pack years (1 pack year = 20 cigarettes smoked per day for 1 year) PFF Cohort: 1. Surgical treatment (fixation or arthroplasty) for a low-energy fracture of the proximal femur (ICD-10 diagnosis S72.0, S72.1, S72.2) as diagnosed on X-rays of the hip and pelvis. Between 3 days and 52 weeks post-surgery 2. Aged 45 years or older (added 14/04/2021) |
| Key exclusion criteria | All participants: 1. Occurrence of any of the following within 3 months prior to informed consent: myocardial infarction, hospitalization for unstable angina, stroke, coronary artery bypass graft (CABG), percutaneous coronary intervention (PCI), implantation of a cardiac resynchronization therapy device (CRTD), active treatment for cancer or other malignant disease, uncontrolled congestive heart disease (NYHA class >3), acute psychosis or major psychiatric disorders or continued substance abuse. PD Cohort: 1. History consistent with Dementia with Lewy Bodies (DLB), atypical parkinsonian syndromes (including multiple system atrophy or progressive supranuclear palsy, diagnosed according to accepted criteria) 2. Repeated strokes or stepwise progression of symptoms, leading to a diagnosis of ‘vascular parkinsonism’ 3. Drug-induced Parkinsonism MS Cohort: 1. Clinical relapse within 30 days prior to screening and baseline. COPD Cohort: 1. Having undergone major lung surgery (e.g. lung transplant) 2. Current diagnosis of lung cancer 3. Primary respiratory diseases other than COPD 4. Substantial limitations in mobility due to factors other than COPD 5. Lung volume reduction within 6 months before inclusion PFF Cohort: 1. Not able to walk before treatment of hip fracture |
| Date of first enrolment | 12/04/2021 |
| Date of final enrolment | 31/07/2023 |
Locations
Countries of recruitment
- Belgium
- England
- France
- Germany
- Greece
- Israel
- Italy
- Norway
- Spain
- Switzerland
- United Kingdom
Study participating centres
Freeman Road
High Heaton
Newcastle-upon-Tyne
NE7 7DN
United Kingdom
Sheffield
S5 7AU
United Kingdom
London
SW3 6NP
United Kingdom
Tel Aviv
64239
Israel
Kiel
24118
Germany
Leuven
3000
Belgium
Barcelona
08036
Spain
Großhansdorf
22927
Germany
Zürich
8006
Switzerland
2nd floor
Athens
106 75
Greece
Erlangen
91054
Germany
Trondheim
7030
Norway
Montpellier
34090
France
Milan
20132
Italy
Sponsor information
Hospital/treatment centre
Newcastle Joint Research Office
Level 1
Regent Point
Newcastle upon Tyne
NE3 3HD
England
United Kingdom
| Phone | +44 (0)1912824461 |
|---|---|
| Tnu-tr.sponsormanagement@nhs.net | |
| Website | http://www.newcastle-hospitals.org.uk/ |
"ROR" |
https://ror.org/05p40t847 |
Funders
Funder type
Research organisation
No information available
Results and Publications
| Intention to publish date | 01/07/2025 |
|---|---|
| Individual participant data (IPD) Intention to share | Yes |
| IPD sharing plan summary | Available on request |
| Publication and dissemination plan | The protocol will be published at later date. There are multiple measures in place to maximise dissemination of the results of the clinical validation study, emphasising a stakeholder-driven dissemination strategy and an Open Access policy. The study will be listed on the ISRCTN registry and included on the NIHR Clinical Research Network Portfolio. Relevant stakeholders for Mobilise-D include the scientific community; patients and patient organisations; health care professionals and public health authorities; pharmaceutical and associated industries; regulatory bodies; and the general public. Scientific dissemination will take place through peer-reviewed publications in scientific journals and presentations at scientific conferences, addressing the main objectives of the study in comprehensive primary papers across all included cohorts, as well as consisting of secondary papers focusing on specific cohorts and sub-questions. Furthermore, scientific dissemination will take place through training of early career researchers through direct involvement in the clinical validation study as PhD students and post-doctoral students, as well as through a Mobilise-D summer school targeting students and young professionals in e.g. (bio-)engineering and medical sciences. The results of the clinical validation study will also be disseminated through popular-science and professional publications in a variety of trade journals and magazines. The wider audience will also be kept appraised of the study results through the Mobilise-D website, social media, newsletters, press releases and project videos. In addition, participants in the clinical validation study will receive feedback in the form of newsletters targeted expressly at them. |
| IPD sharing plan | The datasets generated from the study will be available upon request. The type of data that will be available is outlined on the study website (https://www.mobilise-d.eu/data). All data is stored in a de-identified manner and no patient identifiable data will be included in the dataset. Consent for sharing the anonymised dataset with the wider research community is obtained from all participants. |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Protocol article | 06/10/2022 | 27/10/2022 | Yes | No | |
| HRA research summary | 28/06/2023 | No | No | ||
| Basic results | version 1.0 | 25/06/2025 | No | No |
Additional files
Editorial Notes
25/06/2025: The basic results have been uploaded as an additional file.
25/10/2024: The intention to publish date was changed from 01/10/2024 to 01/07/2025.
10/07/2024: The following changes were made to the trial record:
1. The overall end date was changed from 06/07/2023 to 25/05/2024.
2. The total final enrolment was changed from 2380 to 2388.
18/07/2023: The following changes were made to the trial record:
1. The overall end date was changed from 31/03/2024 to 06/07/2023.
2. The total final enrolment was added.
21/03/2023: The recruitment end date was changed from 31/03/2023 to 31/07/2023.
27/10/2022: The following changes were made to the trial record:
1. Publication reference added.
2. The primary outcome measure was changed.
3. The secondary outcome measures were changed.
18/03/2022: The recruitment end date was changed from 31/03/2022 to 31/03/2023. IPD sharing statement added.
19/07/2021: The following changes were made to the trial record:
1. The overall end date was changed from 12/10/2023 to 31/03/2024.
2. The recruitment end date was changed from 12/10/2021 to 31/03/2022.
3. The inclusion criteria were changed.
4. The plain English summary was updated to reflect these changes.
14/04/2021: The following changes were made to the trial record:
1. The recruitment start date was changed from 01/04/2020 to 12/04/2021.
2. The recruitment end date was changed from 01/04/2021 to 12/10/2021.
3. The overall end date was changed from 09/04/2021 to 12/10/2023.
4. The trial participating centre "Royal Brompton and Harefield NHS Foundation Trust" was changed to "Guys and St Thomas’ NHS Foundation Trust"
5. The inclusion criteria were updated.
6. The plain English summary was updated to reflect these changes.
7. The ethics approval was added.
05/01/2021: The following changes were made to the trial record:
1. A scientific contact was added.
2. The recruitment end date was changed from 01/10/2020 to 01/04/2021.
3. The overall end date was changed from 01/03/2024 to 09/04/2021.
4. The plain English summary was updated to reflect these changes.
10/12/2020: Trial's existence confirmed by the Innovative Medicines Initiative.
